Loading...
Benefits of sodium–glucose cotransporter-2 (SGLT-2) inhibitors for patients with type 2 diabetes are well known, but genitourinary infections can limit their use. Clinicians often recommend stopping these drugs after an incident urinary tract infection (UTI), although the effects of discontinuation on downstream outcomes are uncertain. To address this uncertainty, researchers analyzed data from ≈62,000 patients with type 2 diabetes in Hong Kong who were taking SGLT-2 inhibitors.
About 6% of patients experienced at least one UTI, and one third of patients who had UTIs subsequently stopped taking SGLT-2 inhibitors.
Compared with patients who didn’t have UTIs, patients who had UTIs had worse outcomes, including primary cardiova…
